5:00 – 8:00pm
San Diego, CA
Free for members | $40 early bird non-members
Fundraising for HealthTech brings you expert insight on raising early-stage capital
in HealthTech and Life Sciences — plus a meet-and-greet with several current JLABS companies!
In Partnership with JLABS
|Meet the Investors:||Moderator:|
Managing Partner, Friedman Bioventure
Dr. Friedman oversees a mixed portfolio of private and public companies in the biotechnology and pharmaceutical space, with an emphasis on platform technologies, oncology, neurodegenerative disease and genomics. He is on the board and is VP of Life Sciences for Tech Coast Angels in San Diego, one of the largest and most active Angel Investment groups in the US. He is a board member of CurePSP, a nationwide foundation funding research and education to benefit patients with Progressive Supranuclear Palsy (PSP) and is the managing director of the PSP Genetics Consortium, an international effort to sequence the genomes of up to 2,500 individuals with PSP, funded by the Tau Consortium, CurePSP and the NIH. He is an active investor, board member or advisor to a number of local companies including some very promising startups here at JLabs.
Senior Principal, Alexandria Venture Investments
Jonathan Kabakoff is a Senior Principal – Science and Technology at Alexandria Real Estate Equities, Inc. and its strategic venture capital arm, Alexandria Venture Investments. In his role, Mr. Kabakoff is responsible for strategic venture capital investments, business development, and tenant underwriting in Alexandria’s San Diego and Seattle cluster locations. While at Alexandria, he has led venture capital investments in more than 40 life science companies primarily in the areas of therapeutics, diagnostics, and life science research tools. Mr. Kabakoff currently serves as an Observer on the Boards of Metacrine, Forge Therapeutics, and Singular Genomics Systems. He is on the board of SparkBio, an invitation-only networking group that brings together up-and-coming life science professionals in San Diego, and is a member of the Biocom Capital Development Committee. Mr. Kabakoff received an honorable mention in the first annual Biocom Life Science Catalyst Awards in 2016. Prior to joining Alexandria, he held research positions at Gen-Probe, Genoptix, and the Burnham Institute for Medical Research. Mr. Kabakoff holds a BS in Chemistry from Stanford University.
Principal, Venture Investments, Johnson & Johnson Innovation – JJDC
Vijay is a Principal of Venture Investments at Johnson & Johnson Innovation, JJDC. Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in California. Vijay focuses on venture investments in biotechnology, pharmaceuticals, and diagnostics.
Prior to joining JJDC, Vijay was a Director of Ventures & Early-Stage Collaborations at AbbVie, where he focused on venture investments and preclinical business development transactions. Prior to AbbVie, Vijay was co-founder and CEO of an early-stage peptide manufacturing company, and an independent consultant to several top-tier life sciences venture capital firms and biopharmaceutical companies. Previously, Vijay led business development at Enlight Biosciences, a seed-stage venture creation firm founded by PureTech Health and partnered with 7 major biopharmaceutical companies. He started his business career as a strategy consultant at the Boston Consulting Group (BCG).
Founder & VP of Research, Truvian Sciences
Dena Marrinucci, PhD is an entrepreneur in the life sciences industry. She joined the founding team at Truvian Sciences in late 2015 and leads R&D and Corporate Development. Prior to Truvian, she developed a novel circulating tumor cell technology and founded Epic Sciences in 2008. During her tenure as CSO at Epic, she oversaw all pharma partnering diagnostic collaborations including strategy, agreements, and execution of projects. Within this role, she established partnerships with 35+ pharma companies, integrating Epic’s liquid biopsy technology into 60+ clinical trials worldwide. She also established and led Epic’s clinical laboratory operations as well as assay development and research groups and worked launch Epic’s first commercial test in collaboration with Genomic Health.
In recognition of her work at Epic, Dena was awarded MIT Technology Review’s Top 35 Innovators under 35 and Foreign Policy’s Top 100 Leading Global Thinkers in 2015. In 2016 she was named one of the top ten Life Science Catalysts in San Diego by Biocom and San Diego Venture Group. She also serves as a committee member of the Life Sciences Special Interest Group at Athena. Dena has a BS in Chemistry from the UVM and a PhD from The Scripps Research Institute in chemical biology.